Periostin levels were higher in pediatric patients with Crohn's disease than in those with ulcerative colitis, correlating inversely with disease activity markers.
Does the expression of periostin, TGF-β, and SLUG correlate with disease activity in pediatric inflammatory bowel disease?
Periostin, TGF-β, and SLUG are elevated in pediatric IBD and may serve as biomarkers of disease activity and mucosal healing.
Absolute Event Rate: 0% vs 0%
Background: Pediatric inflammatory bowel disease (pIBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic intestinal inflammation and fibrosis. Identifying molecular mediators involved in inflammation and tissue repair is critical for improving disease management. Objective: To examine the expression of periostin, TGF-β, and SLUG in pIBD and assess their potential roles in intestinal inflammation, fibrosis, and mucosal healing. Methods: Intestinal biopsies from 33 pediatric patients (11 CD, 22 UC) and 10 healthy controls were analyzed immunohistochemically. Quantitative PCR evaluated POSTN, TGF-β1, and SNAI2 expression in 22 patients and 6 controls. Correlations with fecal calprotectin, the Pediatric Crohn’s Disease Activity Index (PCDAI), and the Pediatric Ulcerative Colitis Activity Index (PUCAI) were determined. Results: Periostin, TGF-β, and SLUG expression were significantly increased in pIBD compared with controls. Periostin levels were higher in CD than in UC. All markers correlated positively at mRNA and protein levels. Notably, periostin showed an inverse correlation with fecal calprotectin and PCDAI scores. Conclusions: Periostin, TGF-β, and SLUG may represent biomarkers of pIBD activity. Periostin appears to mediate inflammation and promote mucosal fibrosis or repair, and its inverse association with disease activity suggests a potential therapeutic role in pIBD.
Sputa-Grzegrzolka et al. (Tue,) reported a other. Periostin levels were higher in pediatric patients with Crohn's disease than in those with ulcerative colitis, correlating inversely with disease activity markers.